TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. develops and commercializes disinfection and decontamination technologies for use in controlled environments and public spaces. Its business centers on hydrogen peroxide-based systems and related application methods sold into healthcare, life sciences, food safety, and other contamination-sensitive settings in the United States and international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEquipment and systems used to apply TOMI's disinfection technology in rooms, surfaces, and enclosed spaces.
Replacement parts, consumables, and application components used with installed systems.
Direct disinfection, decontamination, and application services performed for customers.
Other commercial arrangements tied to the company's proprietary technology and related offerings.
Customers
TOMI sells to organizations that need validated disinfection and contamination control, especially where hygiene standards are critical. Typical buyers include hospitals, laboratories, pharmaceutical and biotech facilities, food processing operators, and commercial or institutional users that need repeatable room and surface treatment.
Hospitals and clinical facilities buy disinfection systems and services for patient rooms, equipment, and high-touch areas.
Labs and research facilities use the technology to reduce contamination risk in controlled environments.
Manufacturers and cleanroom operators buy decontamination solutions to support sterile operations.
Processors and related facilities use sanitation solutions to support hygiene and compliance.
Schools, offices, transportation, and other public venues may purchase disinfection systems or services.
Strategy
TOMI's strategy is centered on commercializing its proprietary disinfection platform across regulated and contamination-sensitive end markets. The company relies on expanding installed usage, broadening customer adoption, and supporting recurring demand through consumables, service work, and application support.
A differentiated technology platform can support customer adoption and pricing power versus commodity cleaning products.
Consumables and service work can create repeat demand after initial system placement.
Healthcare, labs, and pharma customers have persistent contamination-control needs and higher switching costs.
Geography
Q1/2026The company is based in the United States and serves domestic customers as well as international markets through commercial sales and distribution relationships. Geography matters because adoption of disinfection technology depends on local regulatory standards, customer budgets, and the presence of healthcare and industrial end markets.
Risks
TOMI depends on customer adoption of a specialized technology platform, so demand can be uneven and tied to capital spending cycles in healthcare and industrial end markets. The company also faces execution risk in scaling sales, supporting installations, and converting interest in disinfection technology into repeatable revenue, while broader risks include competition from alternative sanitation methods and regulatory or validation requirements.
A niche commercial model requires effective sales, installation, and service execution to convert pipeline into revenue.
Exposure: Company-wide
The business depends on customers choosing a specialized disinfection platform rather than standard cleaning or competing technologies.
Alternative disinfectants, UV systems, and contract cleaning providers can reduce demand for TOMI's systems and services.
Exposure: All end markets
Customers in regulated environments often require proof of efficacy and compliance before adoption.
Exposure: Healthcare and life sciences
Accounting
Judgemental itemsSystem sales, consumables, and decontamination services may be recognized at different points in time, affecting quarterly comparability.
Impact: Reported revenue mix and timing
The 2025 private placement notes include conversion features and interest, which may require separate accounting treatment and valuation judgments.
Impact: Debt balance, interest expense, and potential dilution
A small customer base and project-based sales can increase credit risk and require reserves.
Impact: Net revenue and receivables
Specialized systems and components may need write-downs if demand or obsolescence changes.
Impact: Gross margin and asset values
Similar listed companies
Publicly listed companies with a comparable business focus.
Titan Environmental Solutions Inc.
TESI · Services-Computer Programming Services
Thermo Fisher Scientific Inc
TMO · Measuring & Controlling Devices, NEC
Thermo Fisher Scientific is a U.S.-based life sciences and laboratory company organized around four segments: Life Sciences Solutions, Analytical Instruments,…
STERIS plc
STE · Orthopedic, Prosthetic & Surgical Appliances & Supplies
STERIS plc provides products and services used to prevent infection and support sterile processing across healthcare and life sciences settings.
Ecolab Inc
ECL · Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
Ecolab makes water treatment, cleaning, sanitizing, and infection-prevention solutions used by industrial, food, healthcare, hospitality, and life sciences customers.
Texas Instruments Incorporated
TXN · Semiconductors & Related Devices
Texas Instruments is a U.S.-based semiconductor company that designs and manufactures analog and embedded processing chips used in a wide range of electronic systems.
United States Antimony Corporation
UAMY · Primary Smelting & Refining of Nonferrous Metals
Last updated: 24/09/2026